2014 Fiscal Year Final Research Report
Induction of Peripheral immune tolerance in Myasthenia Gravis Patients
Project/Area Number |
24590215
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Medical pharmacy
|
Research Institution | Tokyo University of Pharmacy and Life Science |
Principal Investigator |
|
Research Collaborator |
MASUDA Masayuki
INOUE Aya
ITO Suguru
AIZAWA Hitoshi
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Keywords | 重症筋無力症 / 制御性B細胞 / B細胞活性化因子 / 免疫寛容 / IL-10 |
Outline of Final Research Achievements |
Myasthenia gravis (MG) is an autoimmune disease which caused by producing anti-ACh-R antibody in plasma cells which was differentiated from B cells. In this study, we showed on B cell activating factor -receptor (BAFF-R) was highly expressed on CD19+ B cells in MG patients. We also evaluated the percentage of IL-10+ regulatory B (Breg) cells on B cells. In the MG patients, the frequency of Breg cells was lower than those in healthy subjects. There was a significant correlation between the expression levels of IL-10-R on B cells and the changing rate of anti ACh-R antibody titer in plasma. From these results, we suggest that BAFF attenuate to activate B cells and stimulate production of anti ACh-R antibody in MG patients. On the other hand, IL-10 affected B cells to suppress the secretion of the autoantibody. In conclusion, induction of peripheral immune tolerance would be useful for MG patients by suppression of BAFF production and induction of IL-10.
|
Free Research Field |
薬理学
|